Lipocine Inc (LPCN) Expected to Announce Earnings of -$0.26 Per Share

Brokerages expect Lipocine Inc (NASDAQ:LPCN) to post earnings per share (EPS) of ($0.26) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Lipocine’s earnings. The lowest EPS estimate is ($0.30) and the highest is ($0.21). Lipocine reported earnings per share of ($0.16) during the same quarter last year, which indicates a negative year over year growth rate of 62.5%. The firm is scheduled to announce its next earnings results on Monday, March 5th.

On average, analysts expect that Lipocine will report full-year earnings of ($1.04) per share for the current fiscal year, with EPS estimates ranging from ($1.11) to ($1.00). For the next fiscal year, analysts anticipate that the firm will post earnings of ($0.85) per share, with EPS estimates ranging from ($0.97) to ($0.63). Zacks Investment Research’s EPS calculations are an average based on a survey of research analysts that follow Lipocine.

Lipocine (NASDAQ:LPCN) last posted its quarterly earnings results on Wednesday, November 8th. The specialty pharmaceutical company reported ($0.22) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.27) by $0.05.

A number of equities research analysts have recently issued reports on LPCN shares. Ladenburg Thalmann Financial Services reiterated a “buy” rating and set a $11.00 price target on shares of Lipocine in a research report on Thursday, January 11th. HC Wainwright reissued a “buy” rating and set a $10.00 price objective on shares of Lipocine in a research note on Friday, December 8th. Finally, Canaccord Genuity cut shares of Lipocine from a “buy” rating to a “hold” rating in a research note on Thursday, January 11th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the company’s stock. Lipocine has an average rating of “Hold” and an average price target of $13.50.

Shares of Lipocine (NASDAQ:LPCN) opened at $1.18 on Wednesday. Lipocine has a 12-month low of $1.18 and a 12-month high of $5.33. The stock has a market cap of $26.07, a P/E ratio of -1.28 and a beta of -0.51.

Several institutional investors and hedge funds have recently modified their holdings of the company. P.A.W. Capital Corp purchased a new position in shares of Lipocine during the 3rd quarter worth approximately $397,000. Goldman Sachs Group Inc. purchased a new position in shares of Lipocine during the 2nd quarter worth approximately $300,000. Vanguard Group Inc. increased its stake in shares of Lipocine by 39.7% during the 2nd quarter. Vanguard Group Inc. now owns 546,027 shares of the specialty pharmaceutical company’s stock worth $2,195,000 after purchasing an additional 155,110 shares in the last quarter. Finally, Ameriprise Financial Inc. grew its stake in Lipocine by 18.2% in the 2nd quarter. Ameriprise Financial Inc. now owns 155,600 shares of the specialty pharmaceutical company’s stock worth $626,000 after acquiring an additional 24,000 shares during the period. 22.12% of the stock is owned by institutional investors and hedge funds.

WARNING: “Lipocine Inc (LPCN) Expected to Announce Earnings of -$0.26 Per Share” was posted by American Banking News and is the property of of American Banking News. If you are viewing this article on another site, it was illegally copied and reposted in violation of US & international trademark & copyright laws. The correct version of this article can be read at

About Lipocine

Lipocine Inc is a specialty pharmaceutical company. The Company is focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. Its primary development programs are based on oral delivery solutions for bioavailable drugs.

Get a free copy of the Zacks research report on Lipocine (LPCN)

For more information about research offerings from Zacks Investment Research, visit

Earnings History and Estimates for Lipocine (NASDAQ:LPCN)

Receive News & Ratings for Lipocine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lipocine and related companies with's FREE daily email newsletter.

Leave a Reply